Legend Biotech’s founding chief scientific officer has left the company without a new destination. Takeda has signed another gene therapy deal with Evozyne to work on protein sequences. Pfizer is rolling out a voluntary retirement scheme in India amid a digital push. And more.
1. Legend Biotech CSO abruptly leaves Johnson & Johnson’s CAR-T partner he co-founded
Hot off an FDA approval for Johnson & Johnson-partnered CAR-T therapy Cavykti, Legend Biotech has bid farewell to its co-founder and chief scientific officer, Frank Fan, M.D., Ph.D. In a revelation that suggests Fan was likely forced out amid an internal power struggle, the former science chief told Fierce Biotech he hasn’t settled on his next gig.
